# Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients

> **NCT00084253** · PHASE4 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 200 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Atazanavir/ Stavidine / Lamivudine
- **DRUG:** Atazanavir-Ritonavir/ Stavidine / Lamivudine

## Key facts

- **NCT ID:** NCT00084253
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2006-08
- **Final completion:** —
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2010-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00084253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00084253, "Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00084253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*